1. Treatment of Multiple Myeloma with Radioactive Iodine and Radioactive Iodinated Serum Albumin
- Author
-
Robert R. Newell, Howard R. Bierman, Sydney F. Thomas, and Joseph P. Kriss
- Subjects
medicine.medical_specialty ,Pathology ,medicine.medical_treatment ,Plasma Cells ,Cell- and Tissue-Based Therapy ,Serum albumin ,Iodine Radioisotopes ,Blood serum ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Platelet ,Serum Albumin ,Multiple myeloma ,Radioisotopes ,biology ,business.industry ,medicine.disease ,Radiation therapy ,medicine.anatomical_structure ,Lymphatic system ,Endocrinology ,biology.protein ,Bone marrow ,Multiple Myeloma ,business ,Iodine ,Hormone - Abstract
Since the lesions of multiple myeloma are widespread, satisfactory control of the disease process would appear possible only with an effective systemic therapeutic agent. Unfortunately, the results of treatment by chemotherapeutic agents such as urethane, steroid hormones, and diamidines remain, by and large, unsatisfactory (1–4). External irradiation has been successful in relieving isolated painful areas, or lesions of unusual size or destructiveness. Radioactive isotopes given internally can irradiate all the lesions but are limited by the tolerable total-body dose. Radioactive phosphorus (P32) has received a trial (5–7) because, in general, leukemic and neoplastic tissues concentrate this isotope preferentially. Radiophosphorus collects preferentially also in the bone marrow, and the dose must be held below that which will produce a severe reduction in granulocytes, platelets, and red blood cells. It seemed logical to try radioactive iodine (I131), which would be evenly distributed in vascularized tis...
- Published
- 1955
- Full Text
- View/download PDF